IRADIMED CORP
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
IRMD$86.94+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Income
| · · · · · · · | |||||
|---|---|---|---|---|---|
| · For the Year Ended · | |||||
| · · December 31, · | |||||
| · · 2023 · 2022 · | |||||
| Net income | | $17,192,776 | | $12,828,487 | |
| Other comprehensive (loss) income: | | | | ||
| Change in fair value of available-for-sale securities, net of tax expense (benefit) of $0 and $0 for the year ended December 31, 2023 and 2022, respectively and $0 and $9,098 for the year ended December 31, 2023 and 2022, respectively | | — | | (10,953) | |
| Realized (gain) loss on available-for-sale securities reclassified to net income, net of tax expense (benefit) of $0 and $0 for the year ended December 31, 2023 and 2022, respectively, and $0 and $1,966 for the year ended December 31, 2023 and 2022, respectively | | — | | (6,059) | |
| Other comprehensive loss | | — | | (17,012) | |
| Comprehensive income | | $17,192,776 | | $12,811,475 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.